Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 years or older
• People who are willing and able to sign a written consent form before any screening takes place
• People who have been diagnosed with advanced, inoperable pancreatic cancer of a specific type (ductal adenocarcinoma or acinar cell adenocarcinoma, including all subtypes), where surgery is not possible
• People whose cancer either stayed stable or partially responded after at least 8 cycles of a chemotherapy combination called FOLFIRINOX (Cohort B), OR people whose cancer has continued to grow after receiving standard chemotherapy treatments (Cohort A)
• People whose cancer returned within six months of completing chemotherapy given after surgery are also eligible for Cohort A (there is no limit on how many prior chemotherapy treatments someone has had)
• People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard scale called the ECOG scale (scores 0–2) (confirm with trial site)
• People who are expected to live for more than 12 weeks
• People whose liver, kidney, and other organ functions are within acceptable levels (confirm with trial site)
• People who have had a hepatitis B blood test before starting — a positive result does not automatically prevent participation, as each case would be reviewed by a specialist
• People who agree to use effective contraception for the period required by the study
• People who have measurable cancer that can be assessed on scans
• People whose cancer tissue, when grown in a laboratory (called a patient-derived organoid), shows sensitivity to one of the drugs used in this trial — this is determined through a specialist review process that considers laboratory results, genetic information, drug safety, and the person's clinical situation
• People who are able to swallow and tolerate oral (by mouth) medication, where applicable

Who may not be able to join:

• People who have, or have had, another cancer whose history or treatment could interfere with assessing how safe or effective this trial's treatment is
• People who received their last chemotherapy dose less than 21 days before the trial start date
• People who still have ongoing side effects from previous cancer treatment rated at a moderate level or above (Grade 2 or higher on a standard scale), except for nerve-related side effects in the hands or feet
• People who have ongoing nerve-related side effects (such as numbness or tingling in hands or feet) rated as severe (Grade 3 or higher)
• People who are currently receiving any other cancer treatment, including chemotherapy, biological therapy, radiation, or hormonal therapy (other than hormone replacement), unless the medication is for supportive care and was started at least one month before joining the trial
• People who have had a serious allergic reaction to a drug that is similar to the one matched for them in this trial — the treating doctor would assess whether it is safe to proceed
• People currently taking blood-thinning medications (such as warfarin or similar) may be able to join unless the specific drug assigned in the trial does not allow it
• People with active and progressing brain metastases (cancer that has spread to the brain); people with previously treated and stable brain metastases may still be eligible, provided they have had no seizures, no significant neurological changes in the past month, have been stable for at least one month after treatment, and are not taking steroids or are only on very low doses
• People with significant pre-existing heart conditions, such as uncontrolled chest pain, uncontrolled irregular heartbeat, or symptomatic heart failure
• People whose heart pumping function (left ventricular ejection fraction) is measured at below 40% on a heart scan
• People who have had a stroke, mini-stroke (TIA), or heart attack within the three months before screening
• People who have had acute gastrointestinal bleeding within one month before screening
• People with other significant medical conditions — such as active infection, severely uncontrolled high blood pressure, or serious psychiatric illness — that the treating doctor considers would make participation unsafe or difficult
• People who are currently breastfeeding
• People who do not meet the specific eligibility requirements for the particular drug selected for them in this trial

Important: Always verify eligibility with the trial site directly before applying.